Shots:

• The approval was based on (MAGNOLIA) & (BGB-3111-AU-003) trial evaluating Brukinsa (320mg, qd, 160mg, bid) in 68 & 20 patients with MZL who had 1 prior anti-CD20-based therapy
• In both studies, 38% & 45% had extranodal MZL, 38% & 25% had nodal MZL,18% & 30% had splenic MZL, ORR (68% & 80%), median response time (2.8mos.) & 6% had unknown subtype in the (MAGNOLIA) trial, serious TEAEs in 40% patients, 6% discontinued treatment due to AEs
• Brukinsa is a BTK inhibitor that improves tolerability by minimizing off-target binding. The company provides a myBeiGene patient support program that enables the patients to access Brukinsa including financial assistance, practical & emotional support

Ref: BeiGene | Image: BeiGene